PDF document = Adobe Acrobat required to view this document.

Get Acrobat Reader, click here Get Acrobat here »

THE ONCOLOGISTS' CORNER

Our Mission for Oncologists, Clinical Trials, and Victims of Mesothelioma

The goal of the Mesothelioma Research Foundation of America (www.mesorfa.org) for Oncologists is to seek better treatment options for mesothelioma patients ultimately leading to a cure. With this goal in mind, the Oncologists' corner provides current mesothelioma information at the health professional level for practicing oncologists who have an interest in mesothelioma. For further information please contact the Chairman of our Medical Advisory Board, Dr. Parkash Gill, M.D. through our research foundation at (800) 909-6376, or email him a message here: Dr. Parkash Gill, M.D.

Characteristics of Malignant Pleural Mesothelioma in Women

Andrea S. Wolf, MD, MPH, David J. Sugarbaker, MD, et. al. --
Brigham and Women's Hospital, Boston, Massachusetts.

Message presented to the Forty-sixth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 25-27, 2010

Malignant pleural mesothelioma is an aggressive cancer disease known to be caused by asbestos exposure. Men have a higher incidence of mesothelioma cancer than women do to a likely increase of occupational asbestos exposure among men. However, women appear to experience better long-term survival from the disease. This report brings the results of a research study on 702 patients in which women demonstrated a survival advantage. The findings support an aggressive approach to treating malignant pleural mesothelioma.

Read the full article

Published: April 29, 2010

Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance

Dr. Parkash S. Gill -- USC Norris Comprehensive Cancer Center
www.aacrjournals.org
Clin Cancer Res 2005;11(12) June 15, 2005
Pg. 4305

Read the full article

Posted: July 9, 2005

Killswitch

Lori Oliwenstien -- USC Health Magazine

In addition to blocking an enzyme responsible for tumor growth and metastasis, the drug VEGLIN appears to slow the growth of the cancer cells themselves. The success of Dr. Alexandra M. Levine, M.D. distinguished Professor of Medicine, chief of hematology at the Keck School of Medicine and the medical director of the USC/Norris Cancer Hospital has treated 37 patients with various types of cancers with the Veglin. "... the results are quite impressive, and we are very pleased so far".

Read the full article

Posted: August 31, 2004

As a professional Oncologist, you will find here some of Dr. Gill's recent technical writing that causes us all to have a great hope.

TECHNICAL DOCUMENT (revision - July 2004):
A Phase II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in the Treatment of Relapsed Malignant Mesothelioma

Top of Page